back to Australia directory
australia clinical guidance

Medicines optimisation and medication safety

A detailed Australian summary of medicines optimisation and medication safety, with source-attributed priorities, a practical workflow, safety escalation and state or territory implementation boundaries.

JurisdictionAustralia
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals practising in Australia
This is an iatroX educational summary of named Australia sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Apply current TGA product information, PBS restrictions, state or territory law, local referral criteria, formulary and antimicrobial policy. A national recommendation does not create uniform service access.

Scope

At every transition, reconcile the most accurate medicine list including non-prescription, complementary, intermittent and recently stopped products. Document indication, intended benefit, dose source, duration and monitoring for each medicine and remove duplicate or indication-free therapy collaboratively. This summary is limited to the population, decisions and escalation boundaries stated in the named source.
sources for this section:Medication Safety Standard

The Bottom Line

  • At every transition, reconcile the most accurate medicine list including non-prescription, complementary, intermittent and recently stopped products.
  • Document indication, intended benefit, dose source, duration and monitoring for each medicine and remove duplicate or indication-free therapy collaboratively.
  • Use generic and brand names when formulations differ and verify modified-release, patch, inhaler and insulin device details.
  • Use shared decision-making that explains alternatives, expected benefit, common and serious harm and what matters to the person, including treatment burden.
sources for this section:Medication Safety Standard

Practical clinical workflow

1

Topic-specific assessment action

At every transition, reconcile the most accurate medicine list including non-prescription, complementary, intermittent and recently stopped products.
2

Topic-specific diagnostic action

Use shared decision-making that explains alternatives, expected benefit, common and serious harm and what matters to the person, including treatment burden.
3

Topic-specific management action

Assign responsibility for laboratory monitoring, repeat authorization and follow-up, and communicate changes promptly to pharmacy and other prescribers.
4

Topic-specific follow-through

High-risk medicines such as anticoagulants, insulin, opioids, methotrexate and lithium need standardized indication and monitoring safeguards.
sources for this section:Medication Safety Standard

Safety boundaries and escalation

  • Report suspected adverse reactions and urgently manage overdose, severe interaction, anaphylaxis, bleeding, serotonin toxicity or another serious medicine harm.
  • Ask how medicines are actually taken and inspect packs or dispensing history when adherence uncertainty affects safety.
sources for this section:Medication Safety Standard

Implementation

The named source is national or binational guidance used in Australia, but referral access, public-health directions, formularies and funded services can still differ by state, territory and health service. Check current TGA product information for medicines. Offer culturally safe care and use the NACCHO鈥揜ACGP National Guide where Aboriginal and Torres Strait Islander preventive or chronic-care recommendations differ.
sources for this section:Medication Safety Standard

Clinical use boundary

This independently written summary is not an official guideline. Check the linked source version, current TGA-approved product information where medicines are involved, and the applicable state, territory and local pathway at the point of care.

sources for this section:Medication Safety Standard

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Australian Commission on Safety and Quality in Health CareMedication Safety StandardNSQHS Standards second edition, current page checked 2026-08-20 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Australia question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.